enVVeno Medical Corporation
NVNONASDAQHealthcare● Active
$10.96
+$0.75(+7.35%)
Market Cap$180873
P/E Ratio—
52W High$196.7
52W Low$8.67
enVVeno Medical Corporation (NVNO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NVNO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$5.89
Est. -$8.40 · +29.9%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
NVNO reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | -$9.10 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$8.40 | -$5.89 | +29.9% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 26, 2026 | -$9.80 | -$10.53 | -7.5% | — | $0.00B | — |
| ▲ Q4 FY2025 | Oct 31, 2025 | -$10.50 | -$8.07 | +23.1% | — | — | — |
| ▼ Q3 FY2025 | Jul 31, 2025 | -$0.28 | -$0.33 | -17.9% | — | — | — |
| ▲ Q2 FY2025 | Apr 30, 2025 | -$0.34 | -$0.22 | +35.3% | — | — | — |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.35 | -$0.30 | +14.3% | — | — | — |
| ▼ Q4 FY2024 | Oct 30, 2024 | -$0.33 | -$0.35 | -6.1% | — | — | — |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
-$9.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$5.89
EPS Est.
-$8.40
EPS Surpr.
+29.9%
Revenue
—
Q1 FY2026
Mar 26, 2026Miss
EPS Actual
-$10.53
EPS Est.
-$9.80
EPS Surpr.
-7.5%
Revenue
—
Q4 FY2025
Oct 31, 2025Beat
EPS Actual
-$8.07
EPS Est.
-$10.50
EPS Surpr.
+23.1%
Revenue
—
Q3 FY2025
Jul 31, 2025Miss
EPS Actual
-$0.33
EPS Est.
-$0.28
EPS Surpr.
-17.9%
Revenue
—
Q2 FY2025
Apr 30, 2025Beat
EPS Actual
-$0.22
EPS Est.
-$0.34
EPS Surpr.
+35.3%
Revenue
—
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.35
EPS Surpr.
+14.3%
Revenue
—
Q4 FY2024
Oct 30, 2024Miss
EPS Actual
-$0.35
EPS Est.
-$0.33
EPS Surpr.
-6.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-2.10 | $-2.10 | $-2.10 | 1 |
| Q3 FY2028 | $-4.55 | $-4.55 | $-4.55 | 1 |
| Q2 FY2028 | $-4.55 | $-4.55 | $-4.55 | 1 |
| Q1 FY2028 | $-4.90 | $-4.90 | $-4.90 | 1 |
| Q4 FY2027 | $-5.25 | $-5.25 | $-5.25 | 1 |
| Q3 FY2027 | $-7.00 | $-7.00 | $-7.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +29.9% | $10.07 | $10.22 | +1.49% |
| ▼ Q1 FY2026 | Mar 26, 2026 | -7.5% | $10.98 | $10.51 | -4.28% |
| ▲ Q4 FY2025 | Oct 31, 2025 | +23.1% | $24.77 | $25.04 | +1.09% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -17.9% | $171.94 | $163.77 | -4.75% |
| ▲ Q2 FY2025 | Apr 30, 2025 | +35.3% | $105.51 | $106.58 | +1.01% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +14.3% | $125.40 | $125.40 | +0.00% |
| ▼ Q4 FY2024 | Oct 30, 2024 | -6.1% | $122.56 | $117.59 | -4.06% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +13.9% | $191.12 | $191.12 | +0.00% |
Q2 FY2026+1.49%
Report Date
May 7, 2026
EPS Beat/Miss
+29.9%
Price Before
$10.07
Price After
$10.22
Q1 FY2026-4.28%
Report Date
Mar 26, 2026
EPS Beat/Miss
-7.5%
Price Before
$10.98
Price After
$10.51
Q4 FY2025+1.09%
Report Date
Oct 31, 2025
EPS Beat/Miss
+23.1%
Price Before
$24.77
Price After
$25.04
Q3 FY2025-4.75%
Report Date
Jul 31, 2025
EPS Beat/Miss
-17.9%
Price Before
$171.94
Price After
$163.77
Q2 FY2025+1.01%
Report Date
Apr 30, 2025
EPS Beat/Miss
+35.3%
Price Before
$105.51
Price After
$106.58
Q1 FY2025+0.00%
Report Date
Feb 27, 2025
EPS Beat/Miss
+14.3%
Price Before
$125.40
Price After
$125.40
Q4 FY2024-4.06%
Report Date
Oct 30, 2024
EPS Beat/Miss
-6.1%
Price Before
$122.56
Price After
$117.59
Q3 FY2024+0.00%
Report Date
Jul 31, 2024
EPS Beat/Miss
+13.9%
Price Before
$191.12
Price After
$191.12
Avg Beat Reaction+0.72%
Avg Miss Reaction-4.36%
Beat Rate5 / 8 quarters
Largest Move-4.75% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NVNO ends December
enVVeno Medical Corporation (NVNO) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-5.89 — beating the analyst consensus of $-8.40 by +29.9%. The next NVNO earnings date is expected around September 1, 2026.
Each quarter, investors track NVNO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NVNO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NVNO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NVNO earnings · 5 questionsenVVeno Medical Corporation's next earnings report is expected around September 1, 2026. NVNO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NVNO historically reports after market close (AMC).
NVNO earnings datewhen is NVNO earningsNVNO next earnings datewhen does NVNO report earningsNVNO earnings calendar
▸ Source: FMP · enVVeno Medical Corporation SEC filings · US GAAP · enVVeno Medical Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026